NCT05265650 - Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

June 30, 2024

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG

BO-112 in combination with ablative radiotherapy (SABR) and nivolumab

Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.

PROCEDURE

Tissue Biopsies

Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.

Trial Locations (1)

RECRUITING

Clínica Universidad de Navarra, Pamplona